Respiratory Syncytial Virus (RSV) News and Research RSS Feed - Respiratory Syncytial Virus (RSV) News and Research
Respiratory syncytial virus (RSV) causes mild, cold-like symptoms in adults and older children. However, it can cause serious problems in young babies, including pneumonia and severe breathing problems. In rare cases it can lead to death. Premature babies and those with other health problems have the highest risk. A child with RSV may have a fever, stuffy nose, cough and trouble breathing. Tests can tell if your child has the virus.

RSV easily spreads from person to person. You can get it from direct contact with someone who has it or it by touching infected objects such as toys or surfaces such as countertops. Washing your hands often and not sharing eating and drinking utensils are simple ways to help prevent the spread of RSV infection. There is currently no vaccine for RSV.
Children admitted in out-of-hours emergencies are at no greater risk of dying

Children admitted in out-of-hours emergencies are at no greater risk of dying

Children admitted to UK intensive care units in out-of-hours emergencies are at no greater risk of dying than children arriving during normal working hours, according to new research. [More]
NIAID findings provide structural basis for developing RSV vaccine

NIAID findings provide structural basis for developing RSV vaccine

An atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody represents a leap toward developing a vaccine for a common-and sometimes very serious-childhood disease. [More]
Research shows respiratory syncytial virus can be transferred during pregnancy to unborn baby

Research shows respiratory syncytial virus can be transferred during pregnancy to unborn baby

The most common cause of lower respiratory tract infections in infants and young children, respiratory syncytial virus (RSV), can be transferred during pregnancy to an unborn baby, according to Cleveland Clinic Children's Hospital research published online this week in the journal PLOS ONE. [More]
Study links genetic variation, wheezing illness to childhood asthma risk

Study links genetic variation, wheezing illness to childhood asthma risk

About 90 percent of children with two copies of a common genetic variation and who wheezed when they caught a cold early in life went on to develop asthma by age 6, according to a study to be published March 28 by the New England Journal of Medicine. [More]
National Jewish Health receives U.S. patent for POPG and related compounds

National Jewish Health receives U.S. patent for POPG and related compounds

Dennis Voelker, PhD, professor of medicine at National Jewish Health, has been awarded a U.S. patent (#8,367,643) for various lipids and related compounds that can inhibit inflammation and infection in the lungs, especially those caused by influenza and respiratory syncytial virus (RSV). [More]
Carbohydrate-rich diet during pregnancy may predict RSV severity in infants

Carbohydrate-rich diet during pregnancy may predict RSV severity in infants

An important predictor of the severity of respiratory syncytial virus (RSV) in infants may be what their mothers ate during pregnancy, according to a Vanderbilt study published in the American Journal of Respiratory and Critical Care Medicine. [More]
Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children. [More]

GSU associate professor receives federal grant to bolster flu vaccine research

Sang-Moo Kang, associate professor at Georgia State University's Center for Inflammation, Immunity and Infection, has received a federal five-year, $3.4 million grant to bolster research that will lead to better flu vaccines and vaccines against respiratory syncytial virus (RSV), a disease for which there is no immunization. [More]

Severe RSV disease may impair innate immune response in infants

Infants with severe lower respiratory tract infection caused by respiratory syncytial virus (RSV) may have a dysfunctional innate immune response that relates to the severity of their disease. [More]

Vaccinating families could protect young babies against RSV infection

Research by the University of Warwick indicates that vaccinating families could protect young babies against a common winter virus which can be fatal for infants under six months. [More]
Gene silencing technology used to fight RSV and influenza

Gene silencing technology used to fight RSV and influenza

New hope has arrived for the fight against two deadly viral infections, RSV and influenza, as Griffith researchers prepare to develop a cutting-edge approach to treatment delivery. [More]
Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights. [More]

Alverix receives FDA 510(k) clearance for new BD Veritor System kit

Alverix, Inc., a world leader in the design and manufacture of next-generation platforms for diagnostic Point-of-Care (POC) testing, today announced that BD Diagnostics, a segment of Becton Dickinson and Company, a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD VeritorTM System for Rapid Detection of respiratory syncytial virus (RSV). [More]
Differences in viral illness patterns play a role in asthma development in urban, suburban children

Differences in viral illness patterns play a role in asthma development in urban, suburban children

Children living in low-income urban areas appear especially prone to developing asthma, possibly related to infections they acquire early in life. In a new study in The Journal of Infectious Diseases, available online, researchers from the University of Wisconsin in Madison investigated viral respiratory illnesses and their possible role in the development of asthma in urban versus suburban babies. [More]

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M. [More]
Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients. [More]
Boosting immune system can help reduce asthma attacks due to viral infections

Boosting immune system can help reduce asthma attacks due to viral infections

Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on Sunday 2 September. [More]
BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line. [More]

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today top-line results from a Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients. [More]
Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights. [More]